Ser362

Site Information
TDKDPNLsEEDKVEP SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 7102987

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 , 4 , 5 )
Disease tissue studied:	melanoma skin cancer ( 3 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 2 ) , 'brain, embryonic' ( 5 ) , Hepa 1-6 (epithelial) ( 4 ) , skin [mGluR1 (mouse), transgenic, TG mutant mice] ( 3 )

Upstream Regulation
Treatments:	insulin ( 2 )

References
1	Sacco F, et al. (2016) Glucose-regulated and drug-perturbed phosphoproteome reveals molecular mechanisms controlling insulin secretion. Nat Commun 7, 13250 27841257 Curated Info
2	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
3	Zanivan S, et al. (2008) Solid tumor proteome and phosphoproteome analysis by high resolution mass spectrometry. J Proteome Res 7, 5314-26 19367708 Curated Info
4	Pan C, Gnad F, Olsen JV, Mann M (2008) Quantitative phosphoproteome analysis of a mouse liver cell line reveals specificity of phosphatase inhibitors. Proteomics 8, 4534-46 18846507 Curated Info
5	Guo A (2007) CST Curation Set: 2677; Year: 2007; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]Q Antibodies Used to Purify Peptides prior to LCMS: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851 Curated Info